Liminatus Pharma, Inc. Class A Common Stock
LIMNHealthcare|Biotechnology|US
$2.54
-0.09 (-3.42%)
Tangible Book / Share
$0.63
Cash / Share
$6.35
About
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Stock Price
-96.0%(1Y)
1M
-31.2%
3M
-50.7%
6M
-75.0%
YTD
-91.7%
1Y
-95.7%
3Y
-99.0%
5Y
-99.0%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$3.4M
Employees1
CEOChris Kim
IPO DateMay 1, 2025
Beta0.75
52-Week Range$2.4 – $141.5
Avg Volume487,253
ExchangeNASDAQ
Websiteliminatuspharma.com
Ownership
Float35.3%
Shares Outstanding1.3M
Recent Insider Trades
Valetudo Therapeutics LLCJ
Jul 2, 20263,448,926 shares @ $0.20
Valetudo Therapeutics LLCDISPOSED
Jun 24, 20264,373,603 shares
Ewon Comfortech Co., Ltd.OTHER
Jun 24, 20260 shares
Iris Acquisition Holdings LLCOTHER
Apr 30, 20250 shares
Lemons II Philip WayneOTHER
Jul 10, 20250 shares
Peers
Recent News
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Sep 29, 2026 · globenewswire.com
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Aug 24, 2026 · globenewswire.com
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
Aug 18, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:19 AM